BridgeBio Pharma, Inc. (BIT:1BBIO)
Italy · Delayed Price · Currency is EUR | Market Cap | 11.19B +83.6% |
| Revenue (ttm) | 503.00M +355.2% |
| Net Income | -625.80M |
| EPS | -3.25 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 60.21 |
| Previous Close | 60.21 |
| Day's Range | 60.21 - 60.21 |
| 52-Week Range | 29.23 - 71.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About BridgeBio Pharma
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ... [Read more]
Financial Performance
In 2025, BridgeBio Pharma's revenue was $502.08 million, an increase of 126.26% compared to the previous year's $221.90 million. Losses were -$724.93 million, 35.3% more than in 2024.
Financial numbers in USD Financial StatementsNews
BridgeBio announces FDA acceptance, priority review of BBP-418 NDA
BridgeBio (BBIO) announced the FDA has accepted for filing its new drug application, or NDA, with Priority Review for oral BBP-418 for the treatment of individuals living with limb-girdle muscular…
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for tr...
BridgeBio downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Martin Auster downgraded BridgeBio (BBIO) to Market Perform from Outperform without a price target While Attruby continues to gain share, increasing “payer-driven risks” into the...
BridgeBio initiated with a Neutral at Citi
Citi analyst Eric Joseph initiated coverage of BridgeBio (BBIO) with a Neutral rating and $82 price target The firm sees the shares as range-bound in the medium term with the…
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
BridgeBio Pharma NASDAQ: BBIO executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three po...
BridgeBio Pharma Transcript: Bank of America Global Healthcare Conference 2026
Strong commercial momentum is driven by Attruby’s differentiation in efficacy, safety, and convenience, with robust pipeline launches expected to add significant revenue. Recent IP clarity and real-world data support confidence in achieving peak sales targets, while launch readiness is underpinned by experienced leadership and expanding patient identification efforts.
BridgeBio shares have ‘clear path’ to $90s, says JPMorgan
JPMorgan views BridgeBio (BBIO) as a top idea and sees a buying opportunity at current share levels. The stock closed Monday down 4% to $64.686. The firm sees a “clear…
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1
BridgeBio announces new data of Phase 3 ATTRibute-CM study at Heart Failure 2026
BridgeBio Pharma (BBIO) announced new data from the Phase 3 ATTRibute-CM study at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology, further demonstr...
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p
BridgeBio price target raised to $110 from $100 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $110 from $100 and keeps a Buy rating on the shares. The company reported solid revenue outperformance in Q1,…
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condit...
BridgeBio price target raised to $130 from $125 at Evercore ISI
Evercore ISI raised the firm’s price target on BridgeBio (BBIO) to $130 from $125 and keeps an Outperform rating on the shares.
BridgeBio price target lowered to $94 from $98 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on BridgeBio (BBIO) to $94 from $98 and keeps an Overweight rating on the shares.
BridgeBio price target raised to $114 from $100 at Bernstein
Bernstein raised the firm’s price target on BridgeBio (BBIO) to $114 from $100 and keeps an Outperform rating on the shares. The firm notes Attruby U.S. product sales of $181M…
BridgeBio files automatic mixed securities shelf
06:10 EDT BridgeBio (BBIO) files automatic mixed securities shelf
BridgeBio Pharma Earnings Call Transcript: Q1 2026
Q1 2026 delivered robust revenue growth, led by Attruby's blockbuster trajectory and expanding market share. Three major launches are on track, supported by strong clinical data and commercial readiness. A $500M share buyback was authorized, reflecting confidence in long-term value.
BridgeBio Pharma Earnings release: Q1 2026
BridgeBio Pharma released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
BridgeBio Pharma Quarterly report: Q1 2026
BridgeBio Pharma has published its Q1 2026 quarterly earnings report on May 7, 2026.
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
PALO ALTO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on develop...
BridgeBio Pharma Slides: Corporate presentation
BridgeBio Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
BridgeBio receives regulatory approval in Brazil for Beyonttra
BridgeBio (BBIO) Pharma announced the Brazilian Health Regulatory Agency, ANVISA, has granted marketing authorization for acoramidis, under the brand name Beyonttra, for the treatment of wild-type or ...
BridgeBio to Participate in May and June Investor Conferences
PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condit...
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to ...
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condit...